![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-host-investor-call-to-discuss-topline-results-of-phase-3-trial-of-mino-lok-antibiotic-lock-solution-302157598.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-achieves-primary-and-secondary-endpoints-in-phase-3-trial-of-mino-lok-antibiotic-lock-solution-302150869.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-second-quarter-2024-financial-results-and-provides-business-update-302145338.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-upcoming-ef-hutton-and-hc-wainwright-investor-conferences-302141737.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-15-million-registered-direct-offering-302128377.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-addition-of-city-of-hope-to-umns-phase-1-trial-of-lymphir-in-combination-with-car-t-for-the-treatment-of-b-cell-lymphoma-302113959.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-ld-micro-invitational-xiv-investor-conference-302108125.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-fda-acceptance-of-the-bla-resubmission-of-lymphir-denileukin-diftitox-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma-302090911.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-secures-2-4-million-through-new-jersey-economic-development-program-302081639.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-filing-of-form-s-3-shelf-registration-statement-to-replace-expiring-prior-shelf-registration-302070667.html